The University of Chicago Header Logo

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 11 24; 375(21):2102.

View in: PubMed